HIV Prevention Preparedness Study in Russia, China, and India
NCT ID: NCT00021775
Last Updated: 2014-01-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
2000 participants
OBSERVATIONAL
2002-04-30
2004-02-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
In order to plan large, long-term studies on the prevention of HIV in different areas of the world, it is necessary to get certain information first. It is important to know about the rate of HIV infection and how to get people to enroll for any future studies. This study will be done at 4 study locations.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effectiveness of a Community-level HIV/STD Prevention Intervention in Promoting Safer Sexual Behaviors in High-risk Populations
NCT00710060
Preventing Sexual Transmission of HIV With Anti-HIV Drugs
NCT00074581
HIV Prevention Preparedness Study
NCT00048282
Preparing for International Prevention Trials Involving HIV-Infected Individuals in Care Settings
NCT01264185
Readiness to Disclose Mother's HIV Diagnosis to Their Children in Beijing, China
NCT03248778
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This study enrolls participants from St. Petersburg, Russia; Xinjiang and Guangxi, China; and Chennai, India who are at high risk for HIV infection due to sexual and/or drug use behaviors. Participants who meet the screening criteria then complete an HIV risk assessment interview, receive HIV pre-test and risk reduction counseling, and undergo phlebotomy for HIV antibody testing. Participants who test positive are referred to available services and studies. Those who test HIV-negative and meet eligibility criteria are enrolled and maintained in follow-up over the next 12 months. Participants complete "locator contacts" at Months 3 and 9 and have follow-up visits at Months 6 and 12 for similar tests as performed at entry. In a substudy of this trial in China, participants will be interviewed about their drug use, social networks, needs, and perceptions about HIV/AIDS. These results will be used by HPTN to design more culturally sensitive and appropriate trials in the future.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Are 16 (Saint Petersburg) or 18 (Xinjiang, Guangxi, and Chennai) years of age or older.
* Are HIV sero-negative.
* Are available for 12 months of study participation.
* Have written consent of parent or legal guardian if under age.
* Are able and willing to provide information on where they can be located or contacted.
* Meet specific risk-group requirements, for women at heterosexual risk, for men at heterosexual risk, and for injection drug users.
Exclusion Criteria
* Have any mental disorders that would cause a problem with the informed consent or study participation.
* Have any condition that, in the opinion of the doctor, would interfere with the study.
14 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
National Institute on Drug Abuse (NIDA)
NIH
National Institute of Mental Health (NIMH)
NIH
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Robert Ryder
Role: STUDY_CHAIR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Guangxi Ctrs. for Disease Control & Prevention and for HIV/AIDS Prevention & Control CRS
Nanning, Guangxi, China
Xinjiang Uygar Autonomous Region Ctr. for Disease Control & Prevention, HPTN Project Office
Ürümqi, Xinjiang, China
St. Petersburg Univ. Biomedical Ctr.
Saint Petersburg, , Russia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
10611
Identifier Type: REGISTRY
Identifier Source: secondary_id
HPTN 033
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.